117 related articles for article (PubMed ID: 24068396)
1. Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma.
Kong L; Zhang G; Wang X; Zhou J; Hou S; Cui W
Rom J Morphol Embryol; 2013; 54(3):499-503. PubMed ID: 24068396
[TBL] [Abstract][Full Text] [Related]
2. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
3. Prognostic significance of DLL4 expression in papillary thyroid cancer.
Zhang YZ; Qin F; Han ZG; Liu Q; Zhou L; Wang YW
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(15):2901-5. PubMed ID: 26241546
[TBL] [Abstract][Full Text] [Related]
4. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
6. [The expression and clinical significance of EphA2 and E-cadherin in papillary thyroid carcinoma].
Liu Y; Miao Y; Li X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jun; 29(11):1020-3. PubMed ID: 26536708
[TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region.
Kaliszewski K; Diakowska D; Strutynska-Karpinska M; Rzeszutko M; Grzegrzolka J; Dziegiel P; Wojtczak B; Sutkowski K
Folia Histochem Cytobiol; 2016; 54(4):193-201. PubMed ID: 28051274
[TBL] [Abstract][Full Text] [Related]
8. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
Hao Y; Jin C; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
[TBL] [Abstract][Full Text] [Related]
13. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z
Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013
[TBL] [Abstract][Full Text] [Related]
14. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
15. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression.
Salajegheh A; Dolan-Evans E; Sullivan E; Irani S; Rahman MA; Vosgha H; Gopalan V; Smith RA; Lam AK
Exp Mol Pathol; 2014 Apr; 96(2):212-8. PubMed ID: 24530443
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
Shi CL; Sun Y; Ding C; Lv YC; Qin HD
Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
[TBL] [Abstract][Full Text] [Related]
19. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
20. High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma.
Li WF; Wang G; Zhao ZB; Liu CA
Clin Endocrinol (Oxf); 2015 Oct; 83(4):572-80. PubMed ID: 25418110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
